Compare Baker Hughes Co (BKR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Merck & Co., Inc. — how do they compare? Baker Hughes Co trades at $56.92 (market cap $57.32B), while Merck & Co., Inc. trades at $123.58 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 5.2× Baker Hughes Co's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| BKR | MRK | |
|---|---|---|
Market Cap | $57.32B | $298.31B |
Sector | Energy | Health |
52-Week High | $69.67 | $129.52 |
52-Week Low | $38.68 | $77.60 |
Enterprise Value | $58.72B | $341.72B |
Dividend Yield | 1.59% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
Merck (MRK) trades at $123.43, down 0.48% on the day, with a bullish technical signal and strong institutional buying. Recent earnings beat expectations in three of the last four quarters, with Q2 2026 results pending. The company's acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, while solid profitability metrics include a net income margin of 13.59% and ROE of 18.97% for 2025.
The outlook remains positive with a consensus price target of $137.30, implying 11% upside. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. Analysts are predominantly bullish, with 68% recommending Buy, supported by robust cash flow and strategic M&A activity to drive long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
